文献速递消化系统肿瘤

伊匹木单抗、纳武利尤单抗和托珠单抗联合立体定向体部放疗治疗难治性胰腺癌的2期研究(TRIPLE-R)

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
PubMed 文献 · Eur J Cancer · 2022-12-10

这项单中心2期研究纳入26例对吉西他滨或氟尿嘧啶类方案进展或不耐受的胰腺癌患者,接受伊匹木单抗、纳武利尤单抗、托珠单抗联合15 Gy立体定向体部放疗。主要终点客观缓解率未观察到缓解,5例(19%)疾病稳定,中位无进展生存期1.6个月,中位总生存期5.3个月。联合方案未达到预设的扩展标准。

要点

  • 26例难治性胰腺癌患者中未观察到客观缓解。
  • 5例(19%;95%CI 7-39)达到疾病稳定。
  • 中位无进展生存期1.6个月,中位总生存期5.3个月。

核心结论

  • 伊匹木单抗、纳武利尤单抗、托珠单抗联合立体定向体部放疗在胰腺癌患者中未达到预设的扩展标准。

研究设计与样本

  • 两部分、单中心、2期研究(NCT04258150)的A部分,纳入对含吉西他滨或氟尿嘧啶方案进展或不耐受的胰腺癌患者。
  • 2020年4月17日至2021年1月25日期间入组并治疗26例患者。
  • 第一周期第1天给予15 Gy立体定向体部放疗。
  • 伊匹木单抗1 mg/kg每6周一次,最多输注2次;纳武利尤单抗6 mg/kg和托珠单抗8 mg/kg每4周一次,直至疾病进展或不可接受毒性,或最长1年。
  • 主要终点为客观缓解率,阈值为15%。

主要发现

  • 数据截止(2022年2月7日)时中位随访时间4.9个月(四分位距2.1-7.7)。
  • 未观察到缓解。
  • 5例(19%;95%CI 7-39)达到疾病稳定。
  • 中位无进展生存期1.6个月(95%CI 1.4-1.7),中位总生存期5.3个月(95%CI 2.3-8.0)。
  • 19例(73%)发生治疗相关不良事件,其中2例(8%)为3级及以上事件。

关键数值与推荐

  • 主要终点客观缓解率阈值为15%,本研究未达到该扩展标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interleukin-6 blockade and radiation combined with immunotherapy may modulate the tumour microenvironment to overcome immune resistance. We assessed the efficacy of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy (SBRT) in patients with refractory pancreatic cancer (PC). METHODS: Patients with PC who had progressive disease (PD) or intolerance to gemcitabine- or fluorouracil-containing regimens were enrolled in Part A of the two-part, single-centre, phase 2 study (NCT04258150). SBRT with 15 Gy was administered on day one of the first cycle. Ipilimumab was administered (1 mg/kg every 6 weeks) for a maximum of two infusions. Nivolumab (6 mg/kg) and tocilizumab (8 mg/kg) were given every four weeks until the PD or unacceptable toxicity, or for up to one year. The primary end-point was the objective response rate, with a threshold of 15%. RESULTS: Twenty-six patients were enrolled and treated between April 17, 2020, and January 25, 2021. The median follow-up time at the time of data cutoff (February 7, 2022) was 4.9 months (interquartile range 2.1-7.7). No responses were observed. Five patients (19%; 95% confidence intervals [CI], 7-39) achieved a stable disease. The median progression-free survival was 1.6 months (95% CI 1.4-1.7), and the median overall survival was 5.3 months (95% CI 2.3-8.0). Overall, 19 (73%) experienced adverse events related to the treatment including two (8%) with grade 3 or higher events. CONCLUSION: The combination of ipilimumab, nivolumab, tocilizumab, and SBRT in patients with PC did not meet the prespecified criteria for expansion for full accrual.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chen IM, Donia M, Chamberlain CA, et al. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Eur J Cancer. 2022. PMID: 36592507. doi:10.1016/j.ejca.2022.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。